Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in Prefilled Syringes for Psoriasis (FEATURE)
NCT01555125Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2012
- Primary completion
- Oct 2016
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in plaque psoriasis, sponsored by Novartis. Primary endpoints: Psoriasis Area and Severity Index 75 Response at 12 weeks and Investigator's Global Assessment 0 or 1 Response at 12 weeks. Started May 2012; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT01555125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01555125.